Opinion|Videos|July 1, 2024
Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC
Author(s)Martin H. Voss, MD, Moshe Ornstein, MD
Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.
Advertisement
Episodes in this series
- Please review some of the other therapies for the treatment of advanced non-clear cell RCC in the front-line setting:
- PAPMET (
Tripathi A et al. JCO 2023 ) - Phase 2 study (Nivo + Cabo): (
Lee CH, et al. ASCO 2023. Abstract 4537 )
Advertisement
Related to this article
The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.
The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.
Ulrich Steidl, MD, PhD, has finalized his Montefiore Einstein Comprehensive Cancer Center senior leadership team.
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5